Nuvectis Pharma, Inc. (NVCT) Stock Forecast
NVCT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $35.40 average of analyst targets
- Upside to target
- +90.3% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.22
- 52-week range
- $5.65 – $28.53
NVCT analyst ratings
6 analystsNumber of analysts at each rating.
NVCT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NVCT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.28 | −$0.21 | −$0.44 | +45.1% | 6 |
| Current fiscal year (2026) | −$1.04 | −$1.17 | −$0.94 | −$1.32 | +21.0% | 6 |
| Next fiscal year (2027) | −$1.15 | −$1.62 | −$0.82 | −$1.04 | −10.4% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NVCT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 6 |
NVCT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NVCT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.25 | −$0.23 | −$0.24 | −$0.24 | −8.4% | 3 up · 0 down |
| Current fiscal year (2026) | −$1.04 | −$1.01 | −$1.01 | −$1.04 | −$1.04 | +0.7% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.06 | −$1.01 | −$1.17 | −$1.15 | −$1.15 | +8.2% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NVCT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NVCT beat in 5 of 12.
What analysts expect from NVCT
6 analysts cover Nuvectis Pharma; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.40, 90.3% above the latest close of $18.60. Analysts expect earnings of −$1.04 per share for 2026, +21.0% from a year earlier. For 2027 the average estimate is −$1.15 per share. Nuvectis Pharma beat the EPS estimate in 5 of the last 12 quarters.
Related: NVCT income statement, NVCT key metrics, NVCT chart. See the NVCT stock overview for the latest quote and news.
NVCT forecast FAQ
What is Nuvectis Pharma's price target?
The average analyst price target for Nuvectis Pharma is $35.40, 90.3% above the latest close of $18.60.
Is Nuvectis Pharma a buy, hold or sell?
Of 6 analysts covering Nuvectis Pharma, 4 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nuvectis Pharma's EPS forecast?
Analysts forecast −$1.04 per share for 2026 (range −$1.17 to −$0.94); for 2027 the estimate is −$1.15.
When does Nuvectis Pharma report earnings?
Nuvectis Pharma is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $-0.22.
Does Nuvectis Pharma usually beat earnings estimates?
Nuvectis Pharma reported EPS at or above the analyst estimate in 5 of the last 12 quarters.